These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 4280522)

  • 1. Inhibition of aldosterone production in diuretic-induced hyperaldosteronism by aldosterone antagonist canrenone in man.
    Erbler HC
    Naunyn Schmiedebergs Arch Pharmacol; 1974; 285(4):395-401. PubMed ID: 4280522
    [No Abstract]   [Full Text] [Related]  

  • 2. The effect of saluretics and spironolactone on aldosterone production and electrolyte excretion in man.
    Erbler HC
    Naunyn Schmiedebergs Arch Pharmacol; 1974; 286(2):145-56. PubMed ID: 4281879
    [No Abstract]   [Full Text] [Related]  

  • 3. Suppression by the spironolactone metabolite canrenone of plasma testosterone in man.
    Erbler HC
    Naunyn Schmiedebergs Arch Pharmacol; 1974; 285(4):403-6. PubMed ID: 4280523
    [No Abstract]   [Full Text] [Related]  

  • 4. Spirolactones: clinical and pharmacologic studies.
    Corvol P; Claire M; Rafestin-Oblin ME; Michaud A; Roth-Meyer C; Menard J
    Adv Nephrol Necker Hosp; 1977; 7():199-215. PubMed ID: 208407
    [No Abstract]   [Full Text] [Related]  

  • 5. A comparison of some extra-renal effects of spironolactone and canrenone.
    Huston GJ; Al-Dujaili EA
    Br J Clin Pharmacol; 1979 Apr; 7(4):385-92. PubMed ID: 444357
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Re-evaluation of the antimineralocorticoid effect of the spironolactone metabolite, canrenone, from plasma concentrations determined by a new high-pressure liquid-chromatographic method.
    Dahlöf CG; Lundborg P; Persson BA; Regårdh CG
    Drug Metab Dispos; 1979; 7(2):103-7. PubMed ID: 38071
    [No Abstract]   [Full Text] [Related]  

  • 7. Inhibition of furosemide-induced kaliuresis in the rat by trilostane, an inhibitor of adrenal steroidogenesis.
    Harding HR; Creange JE; Potts GO; Schane HP
    Proc Soc Exp Biol Med; 1984 Dec; 177(3):388-91. PubMed ID: 6595676
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized comparison of metoclopramide and domperidone on plasma aldosterone concentration and on spironolactone-induced diuresis in ascitic cirrhotic patients.
    D'Arienzo A; Ambrogio G; Di Siervi P; Perna E; Squame G; Mazzacca G
    Hepatology; 1985; 5(5):854-7. PubMed ID: 4029895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antagonism of endogenous mineralocorticoids in normal subjects by prorenoate potassium and spironolactone.
    Levine D; Ramsay L; Auty R; Branch R; Tidd M
    Eur J Clin Pharmacol; 1976 Mar; 09(5-6):381-6. PubMed ID: 786663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relative potency of prorenoate and spironolactone in normal man.
    Ramsay L; Harrison I; Shelton J; Tidd M
    Clin Pharmacol Ther; 1975 Oct; 18(4):391-400. PubMed ID: 1100306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proceedings: On the role of diuretic-and spironolactone-induced hyperaldosteronism on electrolyte excretion in man.
    Erbler H
    Naunyn Schmiedebergs Arch Pharmacol; 1974; 282(Suppl):suppl 282:R19. PubMed ID: 4276539
    [No Abstract]   [Full Text] [Related]  

  • 12. Canrenoate in normal man.
    Mroczek WJ; Davidov ME; Horoschak A; Finnerty FA
    Clin Pharmacol Ther; 1974 Aug; 16(2):336-42. PubMed ID: 4368469
    [No Abstract]   [Full Text] [Related]  

  • 13. Sodium excretion and sodium-free volume expansion in dogs: effect of inhibition of aldosterone activity by canrenoate.
    Bie P
    Acta Physiol Scand; 1976 Oct; 98(2):272-4. PubMed ID: 983738
    [No Abstract]   [Full Text] [Related]  

  • 14. Spironolactone and potassium canrenoate in normal man.
    Ramsay L; Shelton J; Harrison I; Tidd M; Asbury M
    Clin Pharmacol Ther; 1976 Aug; 20(2):167-77. PubMed ID: 780038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aldosterone antagonism studies in the rhesus monkey.
    Hofmann LM; Pedrera HA; Suleymamov OD
    J Pharmacol Exp Ther; 1977 Jul; 202(1):216-20. PubMed ID: 406381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of spironolactone, canrenone and canrenoate-K in humans.
    Sadée W; Dagcioglu M; Schröder R
    J Pharmacol Exp Ther; 1973 Jun; 185(3):686-95. PubMed ID: 4712657
    [No Abstract]   [Full Text] [Related]  

  • 17. Adaptation to the natriuretic actions of hydrochlorothiazide, frusemide and amiloride, by rats.
    Ilett KF; Lockett MF
    J Pharm Pharmacol; 1972 Apr; 24(4):302-12. PubMed ID: 4402838
    [No Abstract]   [Full Text] [Related]  

  • 18. Assessment of the antimineralocorticoid effect of RU 28318 in healthy men with induced exogenous and endogenous hypermineralocorticism.
    Ulmann A; Bertagna C; Le Go A; Husson JM; Tache A; Sassano P; Menard J; Corvol P
    Eur J Clin Pharmacol; 1985; 28(5):531-5. PubMed ID: 3899674
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of aldosterone antagonist canrenone on plasma aldosterone concentration and plasma renin activity, and on the excretion of aldosterone and electrolytes by man.
    Erbler HC; Wernze H; Hilfenhaus M
    Eur J Clin Pharmacol; 1976 Feb; 9(4):253-7. PubMed ID: 971711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 3- (16Beta,17beta-dihydroxy-3-oxoandrost-4-en-17alpha-yl) propionic acid gamma-lactone, its preparation and antimineralocorticoid activity.
    Chinn LJ; Hofmann LM
    J Med Chem; 1973 Jul; 16(7):839-43. PubMed ID: 4725930
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.